DCLL9718A

DCLL9718A is an antibody-drug conjugate (ADC) developed for the treatment of acute myeloid leukemia (AML). It comprises a humanized IgG1 anti–C-type lectin-like molecule-1 (CLL-1) monoclonal antibody (MCLL0517A, also known as hu6E7.N54A), which targets CLL-1, a receptor expressed on monocytes, neutrophils, and AML blast cells but not on hematopoietic stem cells. The antibody is linked via a cleavable disulfide-labile linker to a pyrrolobenzodiazepine (PBD) dimer payload, a DNA alkylating agent. This design allows for selective cytotoxicity against AML blasts, with preclinical and early phase clinical development evidence demonstrating target engagement, measurable pharmacodynamics (notable reduction in monocytes and neutrophils), and stable drug conjugation in vivo and in vitro[1][2][3][10].

Other names

anti-CLL1-PBD ADC DCLL9718Santi-CLL-1-PBD ADC DCLL9718Santi-CLL 1-PBD ADC DCLL9718S